Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States. The company's flagship product is the t:slim X2 insulin delivery system that comprises t:slim X2 pump, its 300-unit disposable insulin cartridge, and an infusion set. It also provides t:flex insulin delivery system that includes t:flex pump, its 480-unit disposable insulin cartridge, and an infusion set; t:slim X2 with G5 integration; and Tandem Device Updater, a PC and Mac-compatible tool that allows users to update their pump's software. In addition, the company offers t:connect diabetes management application, a cloud-based data management application, which provides a visual way to display therapy management data from the pump and supported blood glucose meters for users, their caregivers, and their healthcare providers; t:lock cartridge and infusion set products; and various pump accessories. Its products in development include automated insulin delivery systems; t:slim X2 with Basal IQ; t:slim X2 with control IQ; t:sport insulin delivery system; and connected (mobile) health mobile application. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was founded in 2006 and is headquartered in San Diego, California.
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Phone858-366-6900
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$107.60 million
Profitability
Miscellaneous
Employees574
OptionableOptionable
Tandem Diabetes Care (NASDAQ:TNDM) Frequently Asked Questions
What is Tandem Diabetes Care's stock symbol?
Tandem Diabetes Care trades on the NASDAQ under the ticker symbol "TNDM."
When did Tandem Diabetes Care's stock split? How did Tandem Diabetes Care's stock split work?
Shares of Tandem Diabetes Care reverse split on the morning of Tuesday, October 10th 2017. The 1-10 reverse split was announced on Monday, October 9th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Monday, October 9th 2017. An investor that had 100 shares of Tandem Diabetes Care stock prior to the reverse split would have 10 shares after the split.
How were Tandem Diabetes Care's earnings last quarter?
Tandem Diabetes Care Inc (NASDAQ:TNDM) released its earnings results on Thursday, November, 1st. The medical device company reported ($0.62) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.34) by $0.28. The medical device company had revenue of $46.30 million for the quarter, compared to analysts' expectations of $42.71 million. Tandem Diabetes Care had a negative return on equity of 204.32% and a negative net margin of 93.07%. The company's revenue was up 71.5% on a year-over-year basis. During the same period in the previous year, the business posted ($3.09) earnings per share. View Tandem Diabetes Care's Earnings History.
When is Tandem Diabetes Care's next earnings date?
What price target have analysts set for TNDM?
12 analysts have issued 12-month price objectives for Tandem Diabetes Care's stock. Their predictions range from $5.50 to $60.00. On average, they anticipate Tandem Diabetes Care's stock price to reach $44.3750 in the next twelve months. This suggests a possible upside of 4.6% from the stock's current price. View Analyst Price Targets for Tandem Diabetes Care.
What is the consensus analysts' recommendation for Tandem Diabetes Care?
12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Tandem Diabetes Care in the last year. There are currently 3 hold ratings and 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Tandem Diabetes Care.
Has Tandem Diabetes Care been receiving favorable news coverage?
Media stories about TNDM stock have trended very positive on Wednesday, according to InfoTrie Sentiment Analysis. InfoTrie ranks the sentiment of media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Tandem Diabetes Care earned a news sentiment score of 3.4 on InfoTrie's scale. They also assigned news articles about the medical device company a news buzz of 1.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the company's share price in the near future.
Who are some of Tandem Diabetes Care's key competitors?
Some companies that are related to Tandem Diabetes Care include Hill-Rom (HRC), Haemonetics (HAE), Penumbra (PEN), ICU Medical (ICUI), Insulet (PODD), Novocure (NVCR), Globus Medical (GMED), Integra Lifesciences (IART), Cantel Medical (CMD), Merit Medical Systems (MMSI), NuVasive (NUVA), Glaukos (GKOS), Irhythm Technologies (IRTC), Mazor Robotics (MZOR) and Atrion (ATRI).
Who are Tandem Diabetes Care's key executives?
Tandem Diabetes Care's management team includes the folowing people:
- Mr. Kim D. Blickenstaff, Pres, CEO & Director (Age 67)
- Mr. John F. Sheridan, Exec. VP & COO (Age 64)
- Mr. Brian B. Hansen, Exec. VP & Chief Commercial Officer (Age 51)
- Ms. Leigh A. Vosseller, Exec. VP, CFO & Treasurer (Age 46)
- Ms. Susan M. Morrison, Exec. VP & Chief Admin. Officer (Age 40)
Who are Tandem Diabetes Care's major shareholders?
Tandem Diabetes Care's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Meeder Asset Management Inc. (0.01%) and Bank of Montreal Can (0.00%). Company insiders that own Tandem Diabetes Care stock include Brian B Hansen, Christopher J Twomey, David B Berger, Dick Allen, John F Sheridan, Kim D Blickenstaff and Richard P Valencia. View Institutional Ownership Trends for Tandem Diabetes Care.
Which institutional investors are selling Tandem Diabetes Care stock?
TNDM stock was sold by a variety of institutional investors in the last quarter, including Bank of Montreal Can. Company insiders that have sold Tandem Diabetes Care company stock in the last year include Brian B Hansen, David B Berger, John F Sheridan and Kim D Blickenstaff. View Insider Buying and Selling for Tandem Diabetes Care.
Which institutional investors are buying Tandem Diabetes Care stock?
TNDM stock was bought by a variety of institutional investors in the last quarter, including Meeder Asset Management Inc.. Company insiders that have bought Tandem Diabetes Care stock in the last two years include Christopher J Twomey, Dick Allen, Kim D Blickenstaff and Richard P Valencia. View Insider Buying and Selling for Tandem Diabetes Care.
How do I buy shares of Tandem Diabetes Care?
Shares of TNDM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Tandem Diabetes Care's stock price today?
One share of TNDM stock can currently be purchased for approximately $42.41.
How big of a company is Tandem Diabetes Care?
Tandem Diabetes Care has a market capitalization of $2.43 billion and generates $107.60 million in revenue each year. The medical device company earns $-73,030,000.00 in net income (profit) each year or ($12.87) on an earnings per share basis. Tandem Diabetes Care employs 574 workers across the globe.
What is Tandem Diabetes Care's official website?
How can I contact Tandem Diabetes Care?
Tandem Diabetes Care's mailing address is 11075 ROSELLE STREET, San Diego CA, 92121. The medical device company can be reached via phone at 858-366-6900 or via email at [email protected]
MarketBeat Community Rating for Tandem Diabetes Care (NASDAQ TNDM)
MarketBeat's community ratings are surveys of what our community members think about Tandem Diabetes Care and other stocks. Vote "Outperform" if you believe TNDM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TNDM will underperform the S&P 500 over the long term. You may vote once every thirty days.
